An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA

BACKGROUND AND OBJECTIVE: Over the past 5 years, adjuvant treatment options for surgically resected stage III melanoma have expanded with the introduction of several novel immune checkpoint inhibitors and targeted therapies. Pembrolizumab, a programmed cell death protein 1 inhibitor, received US Foo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bensimon, Arielle G., Zhou, Zheng-Yi, Jenkins, Madeline, Song, Yan, Gao, Wei, Signorovitch, James, Krepler, Clemens, Scherrer, Emilie, Wang, Jingshu, Aguiar-Ibáñez, Raquel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311503/
https://www.ncbi.nlm.nih.gov/pubmed/32418051
http://dx.doi.org/10.1007/s40261-020-00922-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311503/
https://www.ncbi.nlm.nih.gov/pubmed/32418051
http://dx.doi.org/10.1007/s40261-020-00922-6

Ejemplares similares